Figure 3 Algorithm for the determination of the clinical

Slides:

Advertisements

Similar presentations

Single immediate postoperative instillation of chemotherapy in patients with Ta/T1 bladder TCC Dr Charles Chabert.

Advertisements

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.

Nat. Rev. Urol. doi: /nrurol

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 4 Types of urinary diversion

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Nat. Rev. Urol. doi: /nrurol

Figure 1 Cellular processes involved in cancer development

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Representative images from a right radical

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Urol. doi: /nrurol

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 1 The development process of the Asian

Figure 3 Drug cycling with collateral sensitivity

Figure 1 Differences in bladder cancer between genders

Figure 13 Proposed management of bladder cancer with variant histology

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Multi-hit model for autoimmune diseases

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 6 Image sequence demonstrating coronal cuts on MRI

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 6 The hexosamine biosynthetic pathway (HBP)

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Target volume definitions

Figure 3 Determination of the primary site

Figure 4 Algorithm for when to determine PTEN

Presentation transcript:

Figure 3 Algorithm for the determination of the clinical significance of concomitant prostate cancer diagnosed at RCP Figure 3 | Algorithm for the determination of the clinical significance of concomitant prostate cancer diagnosed at RCP. Patients whose clinical characteristics are similar to those shown in left side of the panel are at risk of having clinically significant prostate cancer and, therefore, require regular follow‑up monitoring, possibly with additional treatment. Patients with at least one of the tumour-specific characteristics of high-risk disease should be considered to have high-risk disease. Patients with clinical characteristics similar to those shown in the right side of the panel have a low risk of clinically significant prostate cancer and, therefore, should receive regular follow‑up monitoring for signs of disease progression. RCP, radical cystoprostatectomy. Lopez-Beltran, A. et al. (2017) Concomitant bladder cancer and prostate cancer: challenges and controversies Nat. Rev. Urol. doi:10.1038/nrurol.2017.124